- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
- Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
- Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
- Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
- Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
- Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
- Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
- Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
More ▼
Key statistics
As of last trade, Xilio Therapeutics Inc (XLO:NSQ) traded at 1.11, 126.51% above the 52 week low of 0.49 set on Dec 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.13 |
---|---|
High | 1.15 |
Low | 1.08 |
Bid | 1.08 |
Offer | 1.11 |
Previous close | 1.15 |
Average volume | 200.06k |
---|---|
Shares outstanding | 36.91m |
Free float | 27.39m |
P/E (TTM) | -- |
Market cap | 42.45m USD |
EPS (TTM) | -2.57 USD |
Data delayed at least 15 minutes, as of May 23 2024 15:15 BST.
More ▼